HC Wainwright Weighs in on Talphera FY2029 Earnings
Stock analysts at HC Wainwright issued their FY2029 earnings estimates for shares of Talphera in a research note issued on ...
HC Wainwright Has Positive Estimate for Talphera Q1 Earnings
Investment analysts at HC Wainwright boosted their Q1 2025 EPS estimates for shares of Talphera in a research report issued ...
RBC Capital Keeps Their Buy Rating on ADC Therapeutics (ADCT)
In a report released on April 3, Gregory Renza from RBC Capital maintained a Buy rating on ADC Therapeutics (ADCT – Research Report), with a ...
Sarepta Therapeutics (SRPT) Gets a Hold from RBC Capital
RBC Capital analyst Brian Abrahams maintained a Hold rating on Sarepta Therapeutics (SRPT – Research Report) on April 3 and set a price target ...